Fc-fusion proteins: new developments and future perspectives.

Czajkowsky DM, Hu J, Shao Z, Pleass RJ. · 2012

Read Fc-fusion proteins: new developments and future perspectives. by Czajkowsky DM, Hu J, Shao Z, Pleass RJ. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3491832.txt.

Introduction

Joining a useful protein to an antibody's Fc tail can make a drug last longer and hit harder, and Daniel M. Czajkowsky, Jun Hu, Zhifeng Shao, and Richard J. Pleass review this Fc-fusion field in 2012. The first example, a CD4 fusion blocking HIV entry into T cells, dates to 1989.

Several Fc-fusion products have since reached the market for a range of diseases. Newer work pushes into vaccines and intravenous immunoglobulin therapy, and outside medicine into affinity reagents for microarray devices. The review gathers strategies to raise efficacy and safety for each use, with extra attention to younger, less-charted applications. Fc domains, the authors show, have become a general engineering platform.

Catalog record

CREATORCzajkowsky DM, Hu J, Shao Z, Pleass RJ.
YEAR2012
COLLECTIONPAPERS
FORMATTXT
FILE SIZE75 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3491832

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Fc-fusion proteins: new developments and future perspectives By Daniel M Czajkowsky, Jun Hu, Zhifeng Shao, Richard J Pleass Published in: EMBO Molecular Medicine DOI: 10.1002/emmm.201201379 ABSTRACT Since the first description in 1989 of CD4-Fc-fusion antagonists that inhibit human immune deficiency virus entry into T cells, Fc-fusion proteins have been intensely investigated for their effectiveness to curb a range of pathologies, with several notable recent successes coming to market. These promising outcomes have stimulated the development of novel approaches to improve their efficacy and safety, while also broadening their clinical remit to other uses such as vaccines and intravenous immunoglobulin therapy. This increased attention has also led to non-clinical applications of Fc-fusions, such as affinity reagents in microarray devices. Here we discuss recent results and more generally applicable strategies to improve Fc-fusion proteins for each application, with particular attention to the newer, less charted areas. INTRODUCTION Fc-based fusion proteins are composed of an immunoglobin Fc domain that is directly linked to another peptide (Fig 1A). The fused partner can be any other proteinaceous molecule of interest, such as a ligand that activates upon interaction with a cell-surface receptor, a peptidic antigen (Ag) against a challenging pathogen or a ‘bait’ protein to identify binding partners assembled in a protein microarray. Most frequently though, the fused partners have significant therapeutic potential, and they are attached to an Fc-domain to endow the hybrids with a number of additional beneficial biological and pharmacological properties. Perhaps most important, the presence of the Fc domain markedly increases their plasma half-life, which prolongs therapeutic activity, owing to its interaction with the salvage neonatal Fc-receptor (FcRn; Roopenian & Akilesh, 2007), as well as to the slower renal clearance for larger sized molecules (Kontermann, 2011). The attached Fc domain also enables these molecules to interact with Fc-receptors (FcRs) found on immune cells, a feature that is particularly important for their use in oncological therapies and vaccines (Nimmerjahn & Ravetch, 2008). From a biophysical perspective, the Fc domain folds independently and can improve the solubility and stability of the partner molecule both in vitro and in vivo, while from a technological viewpoint, the Fc region allows for easy cost-effective purification by protein-G/A affinity chromatography during manufacture (Carter, 2011). In addition, most Fc-fusions are expressed as homodimers, and, as will be described later, can now be modified to polymerize into well-defined complexes containing twelve fused partners (Fig 1C). Thus an increase in avidity, and with it potency, from an isolated fused partner is also a significant advantage of Fc-fusion proteins. [Figure: The structure of a prototypic IgG Fc-fusion and the means by which it can be presently modifiedFc-fusions are homodimers in which an Fc domain of an antibody is covalently linked to another protein. The fusion partner is usually directly attached to the flexible hinge (as shown), the length and sequence of which varies between different IgG subclasses. Also shown is the approximate position of the N-linked oligosaccharides attached at Asn 297 in the IgG1 Fc-domain.There are a number of specific changes to the (monomeric) fusion construct that can be made to improve efficacy, as detailed in the text. A summary of these specific changes is included in Supporting Information Table S2.Fc-fusions can also be polymerized through engineered disulphide bridges localized to the CH2–CH3 junction and 18 amino-acid carboxy-terminal extensions known as tailpieces. The panel on the right shows atomic force microscopy images of hexameric hIgM-Fc fusions (attached to a malarial antigen) showing six-fold symmetric star-shaped complexes. The smaller radial projections are most likely the antigens (reproduced with permission; Mekhaiel et al, 2011b). Each panel is 75 × 75 nm2.] Hence, as might be expected, the greatest focus of present work with Fc-fusions has been in therapeutic applications and there have been several recent notable successes (Table 1). Still, some of the most exciting advances with Fc-fusions will undoubtedly emerge from their more recent application in areas such as vaccines and microarray technologies. While much of this work has been focused on the specific details of the fused partner, there is also wide understanding of the significant tailoring that must be performed on the Fc-domain to maximize the effectiveness in each particular setting (Fig 1B; Strohl, 2009). In this perspective, we focus on recent results particularly related to the engineering of the Fc-domain for specific applications, and discuss potential future directions, with emphasis on the more novel, less investigated areas of application. [Table: Key Fc-fusion proteins and monoclonal antibodies (mAbs) in the clinic] FC-FUSION PROTEINS AS DRUGS As of the end of 2011, six Fc-fusion based drugs were on the market, with four in phase 3 clinical trials and many others at different stages of pre-clinical development (Table 1). The advantages of Fc-fusion drugs over other types of biopharmaceuticals have been extensively reviewed recently (Beck & Reichert, 2011; Nelson & Reichert, 2009; Strohl, 2009; Strohl & Knight, 2009). In terms of market value, Fc-fusion proteins and monoclonal antibodies (mAbs) together account for 43% of all therapeutic proteins based on published sales in 2008 (Strohl & Knight, 2009), and examination of those in the clinical pipeline suggests that this market share is likely to rise still further (http://clinicaltrials.gov/). In fact, global sales of the most successful Fc-fusion, etanercept, with USD $7.3 billion in 2010, exceeded the most successful therapeutic IgG (bevacizumab) with USD $6.9 billion (Beck & Reichert, 2011). With such commercial successes, Fc-fusions now represent 20% of all antibody-based medicines with FDA approval, fuelling the development of second- and third-generation versions, examples of which are discussed below. Most of these Fc-fusions target receptor-ligand interactions, working either as antagonists to block receptor binding (e.g. etanercept, aflibercept, rilonacept, belatacept, abatacept) or as agonists to directly stimulate receptor function to reduce (e.g. alefacept) or increase immune activity (e.g. romiplostim). These are also common targets for therapeutic mAbs (Reichert, 2011), which have been studied for a much longer period of time than Fc-fusions, although they can actually be considered as a particular type of Fc-fusion construct (Table 1). Evidence from studies with therapeutic mAbs may therefore usefully inform on how improvements to Fc-fusion proteins can be made. As will be made clear, the desired effect of these medications and the range of interactions with Fc effector systems are intimately linked. Increasing effector function Many therapeutic mAbs (e.g. rituximab, trastuzumab, alemtuzumab) function by targeting cancer cells for destruction by natural killer (NK) cells through antibody-dependent cell-mediated cytotoxicity (ADCC; Table 1), a cytolytic effector mechanism believed owing to Ag-specific IgG1 binding FcγRIIIA localized on the NK cells (Congy-Jolivet et al, 2007; Strohl, 2009). The absolute requirement for NK cells is however coming under scrutiny as in vivo work in mouse models also implicates monocytes/macrophages as important effector cells (Biburger et al, 2011). Still, patients with high affinity FcγRIIIA variants respond better to therapy (Veeramani et al, 2011) and interactions with this receptor are thought critical for ADCC (Strohl, 2009). Enhancing the affinity of mAbs for FcγRIIIA was therefore expected to improve tumour killing through ADCC. This was subsequently achieved by modifying the amino acid sequence in the Fc domain or by de-fucosylation of the N-linked oligosaccharides on the Fc region (Shinkawa et al, 2003; Stavenhagen et al, 2008). Such modifications have also been shown to improve the therapeutic

Read the complete text